ASPIRA PATHLAB & DIAGNOSTICS
|
|
| BOM : 540788     NSE :      | |
| LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Upward Pledged Shares : None or < 25% |
Jun 02,2026 |
|
Price(EOD): ₹ 128.05
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Hospital & Healthcare Services |
| MCap: ₹ 131.89 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ASPIRA PATHLAB & DIAGNOSTICS | 3.1% | 97.2% | 141.9% |
| APOLLO HOSPITALS ENTERPRISE | -2% | 6% | 14.6% |
| MAX HEALTHCARE INSTITUTE | -4.4% | -4.4% | -19% |
| FORTIS HEALTHCARE | -3.8% | 0.7% | 31.8% |
| ASTER DM HEALTHCARE | -4.1% | 3.7% | 31.4% |
| NARAYANA HRUDAYALAYA | 2.3% | 9.5% | 9.3% |
| GLOBAL HEALTH | -2.5% | 7.2% | -3.6% |
| KRISHNA INSTITUTE OF MEDICAL SCIENCES | -2.8% | 12.1% | 15.1% |
| DR LAL PATHLABS | -2.4% | 14.2% | 10.8% |
FUNDAMENTAL ANALYSIS OF ASPIRA PATHLAB & DIAGNOSTICS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ASPIRA PATHLAB & DIAGNOSTICS
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
51.52
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 2.56 Cr
[Latest Qtr - Jun2025 - Consolidated Results ] 10.83
P/B Calculated based on Book Value of Rs 12.17 Cr
[Latest Year - Mar2025 - Consolidated Results ] 5.83
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 22.61 Cr
[Latest Qtr - Jun2025 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
165% 112% 113% |
SHARE PRICE MOMENTUM OF ASPIRA PATHLAB & DIAGNOSTICS
ASPIRA PATHLAB & DIAGNOSTICS vs SENSEX
DEBT OF ASPIRA PATHLAB & DIAGNOSTICS
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
0.1 0.11 0.08 0.1 |
0.1 0.11 - 0.07 |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF ASPIRA PATHLAB & DIAGNOSTICS
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF ASPIRA PATHLAB & DIAGNOSTICS
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
-9.16% -22.03% -34.99% -34.99% |
13.18% 134.57% 3037.5% 3037.5% |
| QtrlyTrend |
0 | |
| Latest Qtr: Jun2025 | ||
| Quarterly Result Analysis → | ||
ASPIRA PATHLAB & DIAGNOSTICS related INDICES
You may also like the below Video Courses
FAQ about ASPIRA PATHLAB & DIAGNOSTICS
Is ASPIRA PATHLAB & DIAGNOSTICS good for long term investment?
As on Jun 02,2026, the Fundamentals of ASPIRA PATHLAB & DIAGNOSTICS look Poor and hence it may not be good for long term investment ! See Financial Performance of ASPIRA PATHLAB & DIAGNOSTICS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ASPIRA PATHLAB & DIAGNOSTICS UnderValued or OverValued?
As on Jun 02,2026, ASPIRA PATHLAB & DIAGNOSTICS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of ASPIRA PATHLAB & DIAGNOSTICS ?
As on Jun 02,2026, the Intrinsic Value of ASPIRA PATHLAB & DIAGNOSTICS is Rs. 60.12 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 48.35
Fair Value [Median EV / Sales Model] : Rs. 60.41
Fair Value [Median Price / Sales Model] : Rs. 60.12
Estimated Median Fair Value of ASPIRA PATHLAB & DIAGNOSTICS : Rs. 60.12
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.